The potential of serum proteomics for detection of cancer: Promise or only hope?

Onkologie

Volumn 29, Issue 11, 2006, Pages 498-499

  Krueger, Karl E ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; PROTEIN;

BLOOD SAMPLING; BREAST CANCER; CANCER DIAGNOSIS; CANCER STAGING; CONTROLLED STUDY; EDITORIAL; HUMAN; MASS SPECTROMETRY; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; PROTEOMICS; SENSITIVITY AND SPECIFICITY;

BLOOD PROTEINS; DIAGNOSIS, COMPUTER-ASSISTED; GENE EXPRESSION PROFILING; HUMANS; NEOPLASM PROTEINS; NEOPLASMS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PROTEOMICS; TUMOR MARKERS, BIOLOGICAL;

EID: 33750376432     PISSN: 0378584X     EISSN: None     Source Type: Journal    
DOI: 10.1159/000096163     Document Type: Editorial

References (14)

1. Adam BL, Qu Y, Davis JW, Ward MD, Clements MA, Cazares LH, Semmes OJ, Schellhammer PF, Yasui Y, Feng Z, Wright GL, Jr.: Serum protein fingerprinting coupled with a pattern-matching algorithm distinguishes prostate cancer from benign prostate hyperplasia and healthy men. Cancer Res 2002;62:3609-3614.
2. Petricoin EF, Ardekani AM, Hitt BA, Levine PJ, Fusaro VA, Steinberg SM, Mills GB, Simone C, Fishman DA, Kohn EC, Liotta LA: Use of proteomic patterns in serum to identify ovarian cancer. Lancet 2002;59:572-577.
3. Zhu W, Wang X, Ma Y, Rao M, Glimm J, Kovach JS: Detection of cancer-specific markers amid massive mass spectral data. Proc Natl Acad Sci U S A 2003;100:14666-14671.
4. Baggerly KA, Morris JS, Edmonson SR, Coombes KR: Signal in noise: evaluating reported reproducibility of serum proteomic tests for ovarian cancer. J Natl Cancer Inst 2005;97:307-309.
5. Diamandis EP: Analysis of serum proteomic patterns for early cancer diagnosis: drawing attention to potential problems. J Natl Cancer Inst 2004;96:353-356.
6. de Noo ME, Deelder A, van der Werff M, Özalp A, Mertens B, Tollenaar R: MALDI-TOF serum protein profiling for the detection of breast cancer. Onkologie 2006;29: DOI: 10.1159/000095933.
7. Ransohoff DF: Lessons from controversy: ovarian cancer screening and serum proteomics. J Natl Cancer Inst 2005;97:315-319.
8. Ransohoff DF: Bias as a threat to the validity of cancer molecular-marker research. Nat Rev Cancer 2005;5:142-149.
9. Hortin GL, Jortani SA, Ritchie JC, Jr., Valdes R, Jr., Chan DW: Proteomics: a new diagnostic frontier. Clin Chem 2006;52:1218-1222.
10. Semmes OJ, Feng Z, Adam BL, Banez LL, Bigbee WL, Campos D, Cazares LH, Chan DW, Grizzle WE, Izbicka E, Kagan J, Malik G, McLerran D, Moul JW, Partin A, Prasanna P, Rosenzweig J, Sokoll LJ, Srivastava S, Srivastava S, Thompson I, Welsh MJ, White N, Winget M, Yasui Y, Zhang Z, Zhu L: Evaluation of serum protein profiling by surface-enhanced laser desorption/ionization time-of-flight mass spectrometry for the detection of prostate cancer: I. Assessment of platform reproducibility. Clin Chem 2005;51:102-112.
11. Villanueva J, Gonzalez A, Cornejo M, Nunez C, Encina S: Osteochondroma of the coronoid process. Med Oral Patol Oral Cir Bucal 2006;11:E289-291.
12. Villanueva J, Shaffer DR, Philip J, Chaparro CA, Erdjument-Bromage H, Olshen AB, Fleisher M, Lilja H, Brogi E, Boyd J, Sanchez-Carbayo M, Holland EC, Cordon-Cardo C, Scher HI, Tempst P: Differential exoprotease activities confer tumor-specific serum peptidome patterns. J Clin Invest 2006;116:271-284.
13. Liotta LA, Petricoin EF: Serum peptidome for cancer detection: spinning biologic trash into diagnostic gold. J Clin Invest 2006;116:26-30.
14. Diamandis EP: Peptidomics for cancer diagnosis: present and future. J Proteome Res 2006;5:2079-2082.